BAMBI GRILLEY to United States Food and Drug Administration
This is a "connection" page, showing publications BAMBI GRILLEY has written about United States Food and Drug Administration.
Connection Strength
0.315
-
Sickle cell disease gene therapy drug expenses and reimbursement: a litmus test for commercial pricing strategy and patient access for curative therapies. Cytotherapy. 2025 May; 27(5):567-570.
Score: 0.216
-
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies. Transplant Cell Ther. 2024 08; 30(8):776-787.
Score: 0.052
-
Gene transfer: regulatory issues and their impact on the clinical investigator and the good manufacturing production facility. Cytotherapy. 2003; 5(3):197-207.
Score: 0.047